Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death of a patient taking Sarepta’s Elevidys raises important safety questions.
Safety Questions Loom in Duchenne as Dyne, Wave and Others Plan FDA Filings Read More »
CEO Bryan Hanson told investors last week that the restructuring plan would save Solventum $120 million annually.
The Johns Hopkins surgeon will helm the agency as layoffs loom and important decisions on treatments for rare and infectious diseases await.
Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, according to the warning letter.
Dexcom’s FDA warning letter reveals unauthorized changes to sensors Read More »
Democrats on the Senate Finance Committee criticized the physician and TV personality ahead of the vote Tuesday for avoiding questions about potential cuts to Medicaid.
A new survey from Athenahealth and the Harris Poll shows physicians are thinking less about quitting their jobs and are more favorable toward AI.
Physician sentiment survey shows returning optimism, decreased quit intentions Read More »
Democrats on the Senate Finance Committee criticized the physician and TV personality ahead of the vote Tuesday for avoiding questions about potential cuts to Medicaid.
WVE-N531, an oligonucleotide, elicited significant functional benefit and reversal of muscle damage in the Phase II FORWARD-53 trial. Wave plans to file for accelerated approval of the candidate in 2026.
Wave’s Duchenne Exon-Skipper Reverses Muscle Damage in Mid-Stage Trial Read More »
The German conglomerate announced a licensing agreement with Puhe BioPharma for a PRMT5 inhibitor used in a variety of cancers. Financial details of the deal were not disclosed.
Bayer Jumps on Chinese Partnership Train with Oncology Deal Read More »
The decision could throw cold water on potential copycat suits seeking to hold large, self-funded employers responsible if they overpay for prescription drugs.
Judge dismisses lawsuit against Wells Fargo over prescription drug costs Read More »
